

## Akums offers Lasmiditan tablet to confront migraine challenges

05 January 2024 | News

Lasmiditan's high central nervous system penetration ensures a more targeted approach to migraine management

In a step towards addressing the persistent challenge of migraine, Akums Drugs & Pharmaceuticals, a contract manufacturing pharmaceutical company, has launched the Lasmiditan tablet. This medication has received approvals from the Drug Controller General of India (DCGI) and the United States Food and Drug Administration (USFDA).

Migraine, a chronic neurovascular disorder affecting millions globally, is characterised by recurrent, severe headaches accompanied by nausea and sensitivity to light and sound.

In a 2019 report, it was revealed that headache disorders, including both migraines and tension-type headaches, have emerged as the most prevalent neurological conditions in India, affecting an astonishing 488 million individuals.

The International Headache Society (IHS) outlines criteria for diagnosing migraine, including specific characteristics and associated symptoms observed in at least five attacks. Two main subtypes, migraine without aura and migraine with aura, present distinct features, with the latter involving focal neurological symptoms preceding or accompanying the headache.

Lasmiditan belongs to the "selective serotonin receptor agonists" class of medications and is specifically designed to alleviate the symptoms associated with migraine headaches. The medication is formulated to interrupt pain signals to the brain and address nerve inflammation contributing to migraine symptoms. Each film-coated tablet of Lasmiditan contains lasmiditan hemisuccinate 57.824 mg/115.65 mg eq. to Lasmiditan 50mg/100mg. By binding with the 5-HT1F receptor, Lasmiditan presents an avenue for migraine relief.